{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:39:32Z","timestamp":1790631572862,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40265-025-02255-0","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:00:22Z","timestamp":1764914422000},"page":"265-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Brensocatib: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-7645","authenticated-orcid":false,"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"20","key":"2255_CR1","doi-asserted-by":"publisher","first-page":"9457","DOI":"10.1021\/acs.jmedchem.6b01127","volume":"59","author":"K Doyle","year":"2016","unstructured":"Doyle K, L\u00f6nn H, K\u00e4ck H, et al. Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate (AZD7986). J Med Chem. 2016;59(20):9457\u201372.","journal-title":"J Med Chem"},{"key":"2255_CR2","doi-asserted-by":"publisher","first-page":"1239151","DOI":"10.3389\/fimmu.2023.1239151","volume":"14","author":"JD Chalmers","year":"2023","unstructured":"Chalmers JD, Kettritz R, Korkmaz B. Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease. Front Immunol. 2023;14:1239151.","journal-title":"Front Immunol"},{"key":"2255_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1656316","author":"D Zhang","year":"2025","unstructured":"Zhang D, Zhang W, Hu P. Dipeptidyl peptidase 1 inhibitors for inflammatory respiratory diseases: mechanisms, clinical trials, and therapeutic prospects. Front Pharmacol. 2025. https:\/\/doi.org\/10.3389\/fphar.2025.1656316.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2255_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaci.2021.03.024","volume":"148","author":"T Delemarre","year":"2021","unstructured":"Delemarre T, Bochner BS, Simon H-U, et al. Rethinking neutrophils and eosinophils in chronic rhinosinusitis. J Allergy Clin Immunol. 2021;148(2):327\u201335.","journal-title":"J Allergy Clin Immunol"},{"key":"2255_CR5","unstructured":"Insmed Incorporated. Brensocatib: US prescribing information. 2025. https:\/\/www.brinsuprihcp.com\/. Accessed 19 Sep 2025"},{"issue":"1","key":"2255_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.01050-2024","volume":"65","author":"JD Chalmers","year":"2025","unstructured":"Chalmers JD, Mall MA, Chotirmall SH, et al. Targeting neutrophil serine proteases in bronchiectasis. Eur Respir J. 2025;65(1):1\u201318.","journal-title":"Eur Respir J"},{"issue":"4","key":"2255_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/23120541.00151-2024","volume":"10","author":"JD Chalmers","year":"2024","unstructured":"Chalmers JD, Burgel PR, Daley CL, et al. Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics. ERJ Open Res. 2024;10(4):1\u201313.","journal-title":"ERJ Open Res."},{"key":"2255_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2023.1208780","volume":"14","author":"J Basso","year":"2023","unstructured":"Basso J, Chen KJ, Zhou Y, et al. The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species. Front Pharmacol. 2023;14:1\u201313.","journal-title":"Front Pharmacol"},{"key":"2255_CR9","unstructured":"Insmed Incorporated. Form 10-Q (7 Aug 2025). 2025. https:\/\/investor.insmed.com\/. Accessed 18 Sep 2025"},{"key":"2255_CR10","unstructured":"Insmed Incorporated. FDA approves BRINSUPRITM (brensocatib) as the first and only treatment for non-cystic fibrosis bronchiectasis, a serious, chronic lung disease [media release]. 12 Aug 2025. https:\/\/investor.insmed.com\/."},{"key":"2255_CR11","unstructured":"Insmed Incorporated. CHMP recommends EU approval of BRINSUPRI\u2122 (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis [media release]. 17 Oct 2025. https:\/\/investor.insmed.com\/."},{"issue":"12","key":"2255_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S2213-2600(22)00261-2","volume":"10","author":"HR Keir","year":"2022","unstructured":"Keir HR, Long MB, Abo-Leyah H, et al. Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. Lancet Respir Med. 2022;10(12):1119\u201328.","journal-title":"Lancet Respir Med"},{"key":"2255_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-025-01550-z","author":"MW Konstan","year":"2025","unstructured":"Konstan MW, Tolle JJ, DiMango E, et al. A phase IIa, single-blind, placebo-controlled, parallel-group study to assess safety, tolerability, and pharmacokinetics\/pharmacodynamics of brensocatib in adults with cystic fibrosis. Clin Pharmacokinet. 2025. https:\/\/doi.org\/10.1007\/s40262-025-01550-z.","journal-title":"Clin Pharmacokinet"},{"key":"2255_CR14","unstructured":"Insmed Incorporated. Form 8-K (12 Jun 2024). 2024. https:\/\/investor.insmed.com\/. Accessed 12 Sep 2025."},{"key":"2255_CR15","unstructured":"Insmed Incorporated. Insmed reports first quarter 2020 financial results and provides business update [media release]. 30 Apr 2020.  https:\/\/investor.insmed.com\/."},{"key":"2255_CR16","unstructured":"Insmed Incorporated. Insmed announces worldwide license agreement with AstraZeneca for oral DPP1 inhibitor [media release]. 5 Oct 2016. https:\/\/investor.insmed.com\/."},{"issue":"22","key":"2255_CR17","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","volume":"383","author":"JD Chalmers","year":"2020","unstructured":"Chalmers JD, Haworth CS, Metersky ML, et al. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2020;383(22):2127\u201337.","journal-title":"N Engl J Med"},{"issue":"5","key":"2255_CR18","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1164\/rccm.202408-1545OC","volume":"211","author":"ED Johnson","year":"2025","unstructured":"Johnson ED, Long MB, Perea L, et al. Broad immunomodulatory effects of the dipeptidyl peptidase-1 inhibitor brensocatib in bronchiectasis: data from the phase 2, double-blind, placebo-controlled WILLOW trial. Am J Respir Crit Care Med. 2025;211(5):770\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"16","key":"2255_CR19","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","volume":"392","author":"JD Chalmers","year":"2025","unstructured":"Chalmers JD, Burgel PR, Daley CL, et al. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2025;392(16):1569\u201381.","journal-title":"N Engl J Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02255-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02255-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02255-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:57:52Z","timestamp":1769849872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02255-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2255"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02255-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}